ClinicalTrials.gg
CompletedNCT01473836Updated Jan 24, 2014Results posted

A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

A Phase 3 interventional study of Metronidazole and Ceftriaxone sodium in Intra-abdominal Infections, sponsored by Pfizer. Completed at 15 sites in Japan. Open to participants aged 16 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-01-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
16 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.

Enrollment
14th of 14
38 · median 144
Started
2011
with 1 other
Phase 3
5 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 9th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 16 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Intraabdominal Infections by Pfizer as a file.
02

Study summary

The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.

03

Conditions studied

  • Intra-abdominal Infections

Keywords

  • Metronidazole
  • intra-abdominal infection
  • pelvic inflammatory disease
  • anaerobe
04

Who can participate

Ages eligible
16 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 years of age or older.
  • Diagnosed with intra-abdominal infections or pelvic inflammatory diseases.
  • Can be obtained a specimen for bacteriological efficacy assessment.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected , intolerance or to Metronidazole, Ceftriaxone sodium, or other cephem antibiotics.
  • Severe renal dysfunction ( \< 30 mL/min.) Reference: Cockcroft-Gault calculation formula.
  • Hepatic dysfunction (, ALT, total > 3 times values).
  • Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Metronidazole

    Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium

    Drug: Metronidazole · Drug: Ceftriaxone sodium

Interventions

  • Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.

  • Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.

    Also known as: ROCEPHIN

06

What researchers measure

Primary outcomes

  1. Clinical Response: Response Rate (Data Review Committee Assessment)

    Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

    Time frame: Baseline to EOT (up to 14 days), TOC

Secondary outcomes

  1. Clinical Response: Response Rate (Investigator Assessment)

    Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

    Time frame: Baseline to EOT (up to 14 days), TOC

  2. Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)

    The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; "number of participants assessed as continuation" over "total number of participants that excluding ones assessed as indeterminate" multiplied by 100.

    Time frame: Baseline to Day 4

  3. Bacteriological Response: Eradication Rate (Data Review Committee Assessment)

    Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

    Time frame: Baseline to Day 4, EOT (up to 14 days), TOC

  4. Bacteriological Response: Eradication Rate (Investigator Assessment)

    Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

    Time frame: Baseline to Day 4, EOT (up to 14 days), TOC

  5. Number of Participants Analyzed for Population Pharmacokinetics (PK) of Metronidazole

    Population pharmacokinetic analysis of Metronidazole is conducted by combining current study data with other Metronidazole studies.

    Time frame: Four samples were taken at any infusion after the first dosing: during infusion, immediately after end of infusion, between 15 and 60 minutes after end of infusion, and between 2 hours and immediately before the start of the next infusion.

07

Results

Posted Dec 10, 2013

Participant flow

Participant flow — Overall Study
MilestoneMetronidazole/Ceftriaxone
Started38
Completed32
Not completed6
Withdrew: Adverse event4
Withdrew: Lack of efficacy1
Withdrew: Does not meet entrance criteria1

Outcome measures

PrimaryClinical Response: Response Rate (Data Review Committee Assessment)

Clinical response was evaluated by the data review committee as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

Time frame:
Baseline to EOT (up to 14 days), TOC
Reported as:
Number · percentage of participants
Clinical Response: Response Rate (Data Review Committee Assessment)
percentage of participantsMetronidazole/Ceftriaxone
End of Treatment (n=30)96.6 (82.2 to 99.9)
Test of Cure (n=30)96.7 (82.8 to 99.9)
SecondaryClinical Response: Response Rate (Investigator Assessment)

Clinical response was evaluated by the investigator as effective (cured or improved), ineffective (not meeting "effective" criteria), or indeterminate at the end of treatment (EOT) and the test of cure (TOC: 7 days after EOT) based on clinical symptoms, ultrasound images and necessity of other treatment. TOC was the primary analysis of this outcome measure. Cured = clinical symptoms and abnormal findings at the start of the study were disappeared and considered other antibiotics were not required during the study and after the assessment time point. Improved = clinical symptoms and abnormal findings at the start of the study were improved and considered other antibiotics were not required during the study and after the assessment time point. Response rate was calculated from the following formula; "number of participants evaluated as effective" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

Time frame:
Baseline to EOT (up to 14 days), TOC
Reported as:
Number · percentage of participants
Clinical Response: Response Rate (Investigator Assessment)
percentage of participantsMetronidazole/Ceftriaxone
End of Treatment (n=30)96.7 (82.8 to 99.9)
Test of Cure (n=29)100.0 (88.1 to 100.0)
SecondaryPercentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)

The appropriateness of treatment continuation was evaluated on Day 4 by the investigator as continuation, discontinuation or indeterminate based on the clinical response. The percentage of participants was calculated from the following formula; "number of participants assessed as continuation" over "total number of participants that excluding ones assessed as indeterminate" multiplied by 100.

Time frame:
Baseline to Day 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)
percentage of participantsMetronidazole/Ceftriaxone
Percentage of Participants Who Was Assessed as Appropriate to Continue Treatment (Investigator Assessment)100.0
SecondaryBacteriological Response: Eradication Rate (Data Review Committee Assessment)

Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the data review committee, at Day 4, at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

Time frame:
Baseline to Day 4, EOT (up to 14 days), TOC
Reported as:
Number · percentage of participants
Bacteriological Response: Eradication Rate (Data Review Committee Assessment)
percentage of participantsMetronidazole/Ceftriaxone
Day 4100.0 (75.3 to 100.0)
End of Treatment100.0 (83.2 to 100.0)
Test of Cure100.0 (83.9 to 100.0)
SecondaryBacteriological Response: Eradication Rate (Investigator Assessment)

Bacteriological response was evaluated as eradication (eradication, presumed eradication or colonization), persistence, or indeterminate by the investigator at the end of treatment (EOT), and the test of cure (TOC: 7 days after EOT). Eradication Rate was calculated from the following formula, "number of participants with bacteria eradication, presumed eradication or colonization" over "total number of participants that excluding ones evaluated as indeterminate" multiplied by 100.

Time frame:
Baseline to Day 4, EOT (up to 14 days), TOC
Reported as:
Number · percentage of participants
Bacteriological Response: Eradication Rate (Investigator Assessment)
percentage of participantsMetronidazole/Ceftriaxone
Day 4100.0 (75.3 to 100.0)
EOT100.0 (83.2 to 100.0)
TOC100.0 (83.9 to 100.0)
SecondaryNumber of Participants Analyzed for Population Pharmacokinetics (PK) of Metronidazole

Population pharmacokinetic analysis of Metronidazole is conducted by combining current study data with other Metronidazole studies.

Time frame:
Four samples were taken at any infusion after the first dosing: during infusion, immediately after end of infusion, between 15 and 60 minutes after end of infusion, and between 2 hours and immediately before the start of the next infusion.

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metronidazole/Ceftriaxone—4/38 (10.5%)30/38 (78.9%)
Most frequent serious events
Most frequent serious events
EventMetronidazole/Ceftriaxone
Infectious peritonitisInfections and infestations1/38
Pelvic inflammatory diseaseInfections and infestations1/38
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/38
Retroperitoneal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/38
Most frequent other events
Showing 10 of 59
Most frequent other events
EventMetronidazole/Ceftriaxone
DiarrhoeaGastrointestinal disorders12/38
Ileus paralyticGastrointestinal disorders5/38
InsomniaPsychiatric disorders5/38
NauseaGastrointestinal disorders4/38
VomitingGastrointestinal disorders4/38
Abdominal distensionGastrointestinal disorders3/38
Abdominal pain upperGastrointestinal disorders3/38
Injection site painGeneral disorders3/38
TinnitusEar and labyrinth disorders2/38
ConstipationGastrointestinal disorders2/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Metronidazole/Ceftriaxone
Mean48.9 ± 16.9
Sex: Female, Male
Sex: Female, Male(Participants)Metronidazole/Ceftriaxone
Female24
Male14
08

Study locations

15 sites
  • Daiyukai First Hospital
    Ichinomiya, Aichi, Japan
  • Hirosaki National Hospital
    Hirosaki, Aomori, Japan
  • National Hospital Organization Chiba Medical Center
    Chiba-shi, Chiba-ken, Japan
  • National Hospital Organization Kokura Medical Center
    Kitakyushu, Fukuoka, Japan
  • National Hospital Organization Fukuyama Medical Center
    Fukuyama, Hiroshima, Japan
  • Hitachi General Hospital
    Hitachi, Ibaraki, Japan
  • Kawasaki Saiwai Hospital
    Kawasaki, Kanagawa, Japan
  • Kumamoto Saishunso National Hospital
    Koushi, Kumamoto, Japan
  • National Hospital Organization Sendai Medical Center
    Sendai-shi, Miyagi-ken, Japan
  • Nagano Prefectural Suzaka Hospital
    Suzaka-shi, Nagano-ken, Japan
  • Iida Municipal Hospital
    Iida, Nagano, Japan
  • National Hospital Organization Nagasaki Medical Center
    Ohmura, Nagasaki, Japan
  • National Hospital Organization Osaka Minami Medical Center
    Kawachinagano, Osaka, Japan
  • Koshigaya Municipal Hospital
    Koshigaya, Saitama, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto, Japan
09

References and documents

Publications

  • Mikamo H, Matsumizu M, Nakazuru Y, Nagashima M. Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan. J Infect Chemother. 2015 Feb;21(2):96-104. doi: 10.1016/j.jiac.2014.10.005. Epub 2014 Nov 28. PubMed 25442806 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Nov 17, 2011
Start
Nov 2011
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Dec 10, 2013
Last update
Jan 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01473836
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Nov 2011
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Dec 10, 2013
Last update
Jan 24, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metronidazole · Ceftriaxone

Start the discussion